1. CNS response to osimertinib in patients with T790M-positive advanced NSCLC: pooled data from two phase II trials. (23rd December 2017) Authors: Goss, G; Tsai, C -M; Shepherd, F A; Ahn, M -J; Bazhenova, L; Crinò, L; de Marinis, F; Felip, E; Morabito, A; Hodge, R; Cantarini, M; Johnson, M; Mitsudomi, T; Jänne, P A; Yang, J C -H Journal: Annals of oncology Issue: Volume 29:Number 3(2018) Page Start: 687 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. LBA12Updated results of activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601). (24th November 2019) Authors: Antill, Y; Kok, P S; Stockler, M R; Robledo, K; Yip, S; Parry, M; Smith, D; Spurdle, A; Barnes, E; Friedlander, M L; Baron-Hay, S; Shannon, C; Coward, J; Beale, P J; Goss, G; Meniawy, T; Andrews, J; Kelly, M; Mileshkin, L Journal: Annals of oncology Issue: Volume 30(2019)Supplement 9 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗